Expanding MRD testing to more patients with colorectal cancer

Giving clinicians Latitude™ when ordering MRD testing

Latitude™ is a tissue-free, blood-based, residual disease test (MRD) that delivers fast and reliable results without the need for tumor tissue. Latitude™ is built using a targeted panel, composed of differentially methylated regions specifically for colorectal cancer (CRC). Latitude™ offers strong performance, with high sensitivity and specificity for detecting residual disease in CRC patients.

Latitude™ Explainer Overview

Latitude™ status post-operatively is highly prognostic

Clinical performance in a 195-patient colorectal cancer study (>1,200 plasma samples) from the CIRCULATE-Japan GALAXY cohort

Patients who tested negative with Latitude™ had significantly longer disease-free survival (DFS) compared to those who tested positive (MRD window HR = 10.0, p < 0.001)¹
58% sensitivity at the post-operative MRD timepoint
84% longitudinal sensitivity during post-definitive treatment surveillance (87% in colon cancer)
97% sample-level specificity
Median lead time of 4.6 months before radiographic relapse

LAT_WB_DFS_MRDWindow_KMCurve_20260205_NAT-8023545

Launch_Announcement_Email_Images_2_600x460

Determine which patients will benefit from ACT

Patients who were Latitude™-negative derived little benefit from adjuvant chemotherapy (ACT), whereas Latitude™-positive patients experienced a clinical benefit from ACT¹
Latitude™ positive patients who did not receive ACT went on to relapse representing a PPV of 100% (26/26)

How to order Latitude™

Latitude™ Workflow

Ready to try Latitude™ for your colorectal cancer patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Nakamura Y, et al. Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study. npj Precision Oncology>. 2026.